

Memo

EudraCT Number: 2017-003363-35

Protocol Number: APL2-CP-AIHA-208

Study Title: An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Sponsor: Apellis Pharmaceuticals, Inc

The clinical trial was discontinued in the EU in January 2019, prior to any subject enrolment. This memorandum is to document that for this reason no results-related information will be posted on EudraCT.